SCHEMBL22409622

SCHEMBL22409622

CC1(C)OC(=O)C(=CC=Cc2csc3ccccc23)C(=O)O1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ KDM4C Q9H3R0 1/20 0.47
▸ CYP2A6 P11509 1/20 0.46
▸ MAOB P27338 1/20 0.42
▸ PTGS1 P23219 1/20 0.42
▸ PTGS2 P35354 1/20 0.42
▸ APP P05067 1/20 0.41
▸ AHR P35869 1/20 0.41
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40
▸ TUBA3C P0DPH7 1/20 0.40
▸ TUBA1B P68363 1/20 0.40
▸ TUBA4A P68366 1/20 0.40
▸ TUBB4B P68371 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409635 0.89 MAPT (0.42) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL22409619 0.76 APP (0.44) ALDH1A1MEN1KMT2AKDM4EPTGS1
SCHEMBL22423748 0.76 APP (0.44) ALDH1A1MEN1KMT2AKDM4EPTGS1
SCHEMBL7544372 0.73 CYP2A6 (0.67) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL22409641 0.73 CYP2A6 (0.67) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL22423782 0.72 APP (0.40) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL22409603 0.72 APP (0.40) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL22409617 0.72 ALDH1A1 (0.46) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL22409593 0.71 APP (0.61) ALDH1A1MAPTTDP1MEN1KMT2A
SCHEMBL22409589 0.71 APP (0.61) ALDH1A1MAPTTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof NATIONAL GUARD HEALTH AFFAIRS (SA) 2021-11-02 — — US disclosed
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF NATIONAL GUARD HEALTH AFFAIRS (SA) 2020-09-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161823-B2 Anticancer 1,3-dioxane-4,6-dione derivatives and method of combinatorial synthesis thereof PDK1, PDHA1, PDHA2 ALDH1A1 7/4885MAPT 4235/4885TDP1 2632/4885
US-20200290975-A1 ANTICANCER 1,3-DIOXANE-4,6-DIONE DERIVATIVES AND METHOD OF COMBINATORIAL SYNTHESIS THEREOF PDK1, PDHA1, PDHA2 ALDH1A1 7/4885MAPT 4235/4885TDP1 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback